Navigation Links
InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
Date:6/29/2010

LOS ALTOS, Calif., June 29 /PRNewswire/ -- InteKrin Therapeutics presented 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® (pioglitazone), yesterday at the American Diabetes Association annual meeting in Orlando, FL.

INT131 besylate (INT131) is a novel, non-TZD, selective oral PPAR-gamma modulator (SPPARM) designed to improve glucose metabolism while minimizing the side effects of the TZD full PPAR-gamma agonists such as Actos®: fluid retention (edema), CHF, bone fracture, and weight gain. The Phase 2b trial, INT131-007, was a 366 patient 24 wk double blind study comparing 4 doses of INT131 to maximal dose Actos® (pioglitazone) or placebo in patients with poorly controlled T2DM on stable dose sulfonylurea (SU) with or without metformin (met). Lower extremity edema was assessed with a predefined scoring tool designed for maximal sensitivity for pitting edema at baseline, 12, and 24 wks. Results show INT131 improved glycemic control as measured by HbA1c comparable to Actos® but without evidence of any significant change in edema compared to baseline or placebo. Substantial edema was noted in the pioglitazone group, consistent with published data. These findings support the SPPARM function of INT131 and suggest it represents a safer insulin sensitizer.

"This data clearly differentiates INT131 besylate from pioglitazone with respect to the important clinical parameter of edema," remarked Dr. Alex DePaoli, Acting Chief Medical Officer of InteKrin Therapeutics, who presented the data. "These findings are consistent with previous clinical data and support the advantages of the SPPARM nature of this agent."

"Insulin
'/>"/>

SOURCE InteKrin Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
5. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
6. InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), ... proprietary technologies and products for advanced microarray diagnostics, ... Master Service Agreement to contract with a UK-based ... During the initial phase of this agreement, SQI ... prototype of one of the customer,s assays, operational ...
(Date:8/21/2014)... , Aug. 21, 2014  Aptuit LLC announces ... Lafayette, Indiana , has enhanced its capabilities ... of small and large molecules, including biologic drugs, ... Bruker maXisPlus Q-TOF mass spectrometer. In ... CEO, Aptuit, said, "The expanded large molecule capability ...
(Date:8/21/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... women,s health, has appointed Holly B. Bauzon ... Ms. Bauzon has a proven track record in ... laboratory services companies. She has more than 20 years ... she held the position of Director, Lab Services Sales ...
Breaking Medicine Technology:SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
(Date:8/22/2014)... UK (PRWEB) August 22, 2014 The ... recent past, specifically in the developing world, has led ... and the number of deaths due to AIDS globally. ... declining, the number of new patients becoming affected by ... conscious efforts being undertaken by all related organisations and ...
(Date:8/22/2014)... Ohio (PRWEB) August 22, 2014 Dayton Children's ... care tower as part of a $141 million campus renewal. ... patient care tower were unveiled to the public. , ... facilities plan that will create a campus that meets the ... future. These new care spaces will embody Dayton Children’s unique ...
(Date:8/22/2014)... PA (PRWEB) August 22, 2014 Menstrual ... An inventor from Sunrise, Fla., decided that there needed ... , Easy to use and producible in design variations, ... stains caused by leaks, which avoids embarrassment and promotes ... to conventional sanitary pads. , The original design was ...
(Date:8/22/2014)... 22, 2014 (HealthDay News) -- Many children get anxious ... but there are a number of ways that parents ... expert suggests. The first step is to explain ... help protect their health, said Rita John, director of ... University School of Nursing in New York City. ...
(Date:8/22/2014)... Cleveland, Ohio (PRWEB) August 22, 2014 A ... the mood-food connection. The summit is no-cost and open ... their best kept secrets, practical tips and advice on how ... to lose or manage weight. Mindful eating is not ... decisions and stay motivated instead of an "eat this, don't ...
Breaking Medicine News(10 mins):Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2Health News:20 Top Experts Discuss How to Unravel the Food-Mood Connection 2
... Golf can be a good investment for the health, according ... Institutet. The death rate for golfers is 40 per cent ... and socioeconomic status, which correspond to a 5 year increase ... safest. , It is a well-known fact that exercise ...
... 2008) Results from a pivotal Phase III ... oral, once-daily, investigational anticoagulant medication, was superior in ... total knee replacement (TKR) surgery. The head-to-head study ... enoxaparin, the current standard of care. , Data ...
... May 30 Lutronic, Inc., one of,the world,s ... today that its MOSAIC eCO2 system, the next ... the deep,ablative features of a CO2 laser, is ... With intuitive touch-screen software, the powerful MOSAIC ...
... May 30 /PRNewswire-FirstCall/ - Predictive medicine company,PreMD Inc. ... been notified by,the American Stock Exchange (the "AMEX") ... for regaining compliance with the continued listing,standards and ... stock from the,Exchange by filing a delisting application ...
... less likely than white women to receive the radiation ... according to a study that Dana-Farber Cancer Institute researchers ... Society of Clinical Oncology in Chicago. , Although the ... that thousands of black and Hispanic breast cancer patients ...
... COLUMBUS, Ohio Medical researchers at The Ohio State ... a $34 million grant from the National Institutes of ... translational protocols that help identify and advance treatments for ... received by Ohio State. , The Ohio State University ...
Cached Medicine News:Health News:Golf prolongs life 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Blacks, Hispanics less likely than whites to receive follow-up radiation for early breast cancer 2Health News:Ohio State receives $34M NIH grant 2
... developed to create physically secured rooms that ... are converted to RFID portals. These Intelli-Storeroom™ ... antennas by VerdaSee's Field Engineering experts. RFID ... that are to be tracked. The assets ...
... enabled Med Station provides a real time ... during anesthesia. The portable workstation automatically tracks ... removed. The system automatically reorders product from ... tracks expiration dates, catalog numbers and lot ...
... VerdaSee Location-ID™ is a family ... track equipment and individuals inside hospitals, ... radio frequency technology. The target tracking ... through a series of radio frequency ...
Assetrac allows identification, location, and protection of your assets....
Medicine Products: